EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
27/03/2026
Voltar para busca
Dado oficial do USPTO
PROPHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
29/03/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
35, 42, 44, 45
Data de depósito
15/12/2022
Data de registro
03/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
03/12/2024
Última transação
29/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
09/01/2023
Primeiro uso no comércio
09/01/2023
Código do desenho
3
Tipo de titular
16
Localização do titular
Raleigh, NC, US
Examinador
BECHHOFER, YOCHEVED D
Unidade examinadora
M50
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of stylized word "propharma"; the "o" in the word has varying ombre-type lines within the letter.
Titulares e representantes
Titulares
ProPharma Group Holdings, LLC
ProPharma Group Holdings, LLC
Representantes
Dianne M. Smith-Misemer HOVEY WILLIAMS LLP
Classificação técnica
Classes Nice
Classe 35Classe 42Classe 44Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Business information and business consulting servicesproviding business advisory services to identifyscreenselect contract manufacturing organizations to contract and build medical and pharmaceutical products and devices; providing business advisory services to health care providersdesigning the administrativefinancial and clinical workflows associated with value-based healthcare delivery models; providing business assistance to healthcare providers in the field of enabling communication and collaboration for the purpose of developingimplementing and evaluating patient care plans; Business servicestracking and monitoring regulatory requirements in the pharmaceuticalbiotechnologymedical fields for business purposes; maintaining files and records concerning the medical condition of individuals; maintaining personal medical history records and files
Classe 42
Providing quality assurance services in the medicalpharmaceuticalbiotechnology fields; Quality management servicesquality evaluation and analysisquality assurancequality controlin the medicalpharmaceuticalbiotechnology fields; Testinganalysisevaluation of medicalpharmaceuticalbiotechnology services to assure compliance with industry standards; Tracking and monitoring regulatory requirements in the pharmaceuticalbiotechnologymedical fields for quality control purposes; consulting services in the field of biotechnology
Classe 44
Medical and pharmaceutical consultation; providing medical and pharmaceutical information servicesdrug interaction call centersadverse event reporting services for drugs and medical devices and product compliant reporting services for drugs and medical device; medical information; providing medical informationconsultancy and advisory services; health care consultingaggregating clinicalclaimssocioeconomic and behavioral health data for the purpose of improving healthcare providers' evaluation of health conditions and health risks with individual patientscohorts of patientspopulations; health care consultingassessing patient and population health profiles using evidence-based medical guidelines for the purpose of improving healthcare provider treatment decisions at the point of care; providing information over a global computer network in the field of health care; providing medical informationconsultancyadvisory servicesproviding healthcare providersinsurance companieshealthcare product manufacturers with information and statistics regarding patient medication intakeschedule compliancehealth status
Classe 45
Regulatory compliance consulting in the pharmaceuticalbiotechnologymedical fields; Regulatory compliance consulting in the fields of drug and device development and manufacturing; Tracking and monitoring regulatory requirements in the pharmaceuticalbiotechnologymedical fields for legal or regulatory compliance purposes; Tracking and monitoring regulatory requirements in the field of drug and device development and manufacturing for regulatory compliance purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/03/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
27/03/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
27/03/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
23/09/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/09/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/09/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
23/09/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
23/09/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/12/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
03/12/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/11/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/11/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
23/10/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
15/10/2024
IUAF
USE AMENDMENT FILED
12/08/2024
EISU
TEAS STATEMENT OF USE RECEIVED
12/08/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
20/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/12/2023
PUBO
PUBLISHED FOR OPPOSITION
26/12/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/12/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
21/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/11/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/11/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/11/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/09/2023
GNRT
NON-FINAL ACTION E-MAILED
21/09/2023
CNRT
NON-FINAL ACTION WRITTEN
21/09/2023
DOCK
ASSIGNED TO EXAMINER
19/09/2023
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
12/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/01/2023
NWAP
NEW APPLICATION ENTERED
19/12/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PROPHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.